Objectives: Advanced pancreatic ductal adenocarcinoma is resistant to systemic chemotherapy, resulting in a poor prognosis. We previously isolated a human pancreatic tumor-initiating cell line, KMC07, from a patient with acquired resistance to gemcitabine chemotherapy. To improve the anticancer effects of gemcitabine, we investigated the molecular mechanism of KMC07 cells' resistance to gemcitabine.
P
ancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related mortality. The nucleoside analogue, gemcitabine, is the established standard treatment choice for advanced PDAC. 1 The FOLFIRINOX treatment protocol (folic acid, fluorouracil, irinotecan, and oxaliplatin) results in an improved overall survival of 11.1 months, compared with 6.8 months in controls using gemcitabine alone, 2 but requires carefully selected patients with good performance status and the absence of several contraindications. Therefore, gemcitabine remains a key drug for treatment, 3, 4 and clarifying the molecular mechanisms related to gemcitabine resistance is important for improving treatment and increasing overall survival. Kras with a constitutively active (CA) mutation is found in almost 95% of PDAC cases. 5, 6 In model systems, the Kras CA mutation induces formation of premalignant lesions in the pancreas, and in combination with a p53 mutation or chronic inflammation, is able to induce PDAC. [7] [8] [9] Because the Kras CA mutation plays a pivotal role in formation of PDAC, small molecular inhibitors targeting Kras signaling molecules have been developed. 10 Their recent clinical application has, however, highlighted that many of these inhibitors activate resistancecausing feedback mechanisms and are a cause for concern regarding their toxicity in the clinic. 4 Extracellular matrix-related proteins are involved in proliferation and metastasis of PDAC. [11] [12] [13] [14] [15] Matrix metalloproteinase-10 (MMP-10) expression is induced in pancreatic cancer and its inhibition results in suppression of metastasis and invasion. 16 Matrix metalloproteinase-10 expression is regulated by Kras signaling in lung cancer stem cells 17 and by histone acetylation in vascular endothelial cells. 18 However, the molecular mechanisms involving MMP-10 that underly gemcitabine-resistant PDAC remain unclear.
We previously isolated gemcitabine-resistant pancreatic tumor-initiating cell lines, KMC cell lines, from advanced PDAC patients who were resistant to gemcitabine chemotherapy. 19 In this study, we examined molecular mechanisms of gemcitabine resistance using one of these cell lines, KMC07.
MATERIALS AND METHODS

KMC07, Stromal, and Pancreatic Cancer Cell Lines
The human pancreatic tumor-initiating cell line KMC07 was isolated from a gemcitabine-resistant PDAC patient. 19 The mouse stromal cell line PA6 (a gift from Dr. Nishikawa [RIKEN, Kobe, Japan]) was maintained in α-minimum essential medium (Invitrogen, Carlsbad, Calif ) containing 10% fetal calf serum.
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KMC07 cells were co-cultured with PA6 cells in serum-free Stem medium (catalog number DSRK100, DS Pharma Biomedical, Osaka, Japan) containing 0.1 μM 2-mercaptoethanol, 50 U/mL of penicillin, and 50 μg/mL of streptomycin (Thermo Fisher Scientific Inc, Rockford, Ill) at 37°C in a humidified atmosphere containing 5% CO 2 . Human pancreatic cancer cell lines: BxPC-3, PANC-1, MIA PaCa-2, and AsPC-1 cells, were obtained from American Type Culture Collection (Rockville, Md).
Engraftment of KMC07 Cells
Approximately 8-week-old male nude mice (BALB/ cAJc1-nu/nu) (CLEA, Tokyo, Japan) were used. All nude mice were housed and used under the approved protocols in accordance with the Kobe University guidelines for the care and use of laboratory animals (permit number: A120905). KMC07 cells cocultured with PA6 cells were harvested, dissociated and suspended in 1 mL of phosphate-buffered saline (PBS). Nonspecific antibody binding was blocked using purified rat antimouse CD16/CD32 monoclonal antibodies (BD Biosciences, San Jose, Calif ) and a human FcR blocking reagent (Miltenyi Biotech, Bergisch Gladbach, Germany) for 15 minutes on ice. KMC07 cells, after blocking, were separated from mouse PA6 cells expressing mouse PDGFRβ by MACS Separator (Miltenyi Biotech) using a biotin-conjugated antimouse PDGFRβ monoclonal antibody (eBioscience, San Diego, Calif ) and antibiotin Microbeads (Miltenyi Biotech) according to manufacturers' protocols. Purities ranged from 95% to 98% for each cell population, evaluated by FACS analyses (data not shown). After a small left abdominal flank incision was made, 200 μL of the separated KMC07 cells (1 Â 10 6 KMC07 cells in 200 μL of serum-free Stem medium) was injected in a region of the pancreas tail using a 1 mL disposable syringe attached to a 30-gauge needle (TERUMO, Tokyo, Japan). One layer of the abdominal wound was closed with an Auto-clip (Clay Adams, Parsippany, NJ). After 8 weeks, the mice were killed under anesthesia. Tissue samples were fixed in 10% phosphate-buffered formalin overnight and embedded in paraffin. For gemcitabine treatment, 8 weeks after injection of KMC07 cells into subcutaneous fat or a region of the pancreas tail, 120 mg/kg of gemcitabine (Eli Lilly Japan KK, Tokyo, Japan) or saline, for controls, was injected intraperitoneally, twice a week for 4 weeks. The mice were then killed under anesthesia. Tissue samples were fixed in 10% phosphatebuffered formalin overnight and embedded in paraffin.
Immunohistochemistry
Immunohistochemical staining was performed as described previously. 21 Immunostaining to detect MMP-10 expression in human tissues was performed on 3-μm sections from formalinfixed, paraffin-embedded tissues, placed on coated glass slides, and dried at room temperature overnight. Sections were dewaxed in xylene and rehydrated according to standard procedures. For antigen retrieval, the tissue sections were boiled in 1Â Target Retrieval Solution pH 9.0 (Dako, Carpinteria, Calif ) for 40 minutes. The samples were cooled at room temperature for 20 minutes and rinsed with distilled water 3 times, followed by peroxidase block with 3% H 2 O 2 in methanol for 5 minutes. After rinsing twice with distilled water, the samples were immersed in Tris-buffered salineTween20 (TBST) (25 mM Tris-HCl [pH 7.4], 75 mM NaCl, and 0.1% Tween20) for 5 minutes and then incubated with a primary antibody (a rabbit antihuman MMP-10 polyclonal antibody (catalog number PA5-29746, Thermo Fisher Scientific Inc) diluted 1:250 in Dako Real antibody diluent (catalog number S202230, Dako, Burlington, Canada) at 4°C overnight. The samples were rinsed 3 times with TBST. The primary antibody detection was performed with rabbit horseradish peroxidase polymer probe (ChemMate DAKO EnVision Detection Kit, Peroxidase/DAB, Rabbit, catalog number K5007; Dako) at room temperature for 30 minutes, followed by 2 rinses with TBST according to the manufacturer's instructions. The signal was developed with diaminobenzidine (Dako) for 10 minutes. The samples were rinsed with distilled water 3 times, counterstained with hematoxylin for 1 minute, and dehydrated in alcohol solution and xylene. Parallel sections were stained with hematoxylin and eosin for identification of cancerous and normal tissues.
Microarrays
KMC07 cells co-cultured with PA6 cells in a 10-cm Corning culture dish (Corning, Corning, NY) were incubated with 2 μM gemcitabine or PBS. After 48 hours, RNAs were extracted using an RNAeasy mini kit (Qiagen, Venlo, Netherland), 22 and subjected to microarray analyses as described. 23 
Reverse Transcription-Polymerase Chain Reaction and Quantitative Real Time-Polymerase Chain Reaction Assays
Reverse transcription-polymerase chain reaction (RT-PCR) was performed as described. 23 quantitative real-time (qRT)-PCR was performed with a QuantiTect SYBR Green RT-PCR kit (catalog number 204243; Qiagen) using the Applied Biosystems 7500 Real-Time PCR System (Life Technologies, Carlsbad, Calif ) according to manufacturers' protocols. 19 Quantification of MMP10 mRNA expression was determined by the relative standard curve method with human β-actin as an endogenous control. The amount of MMP10 promoter genomic DNA immunoprecipitated in chromatin immunoprecipitation (ChIP) assays was quantified using PCR. The primer sequences used were:
human-β-actin-F/104: 5′-AGCCTCGCCTTTGCCGATCC-3′ human-β-actin-R/104: 5′-TTGCACATGCCGGAGCCGTT-3′ human-MMP-10-F/119: 5′-AGTTTGGCTCATGCCTACCC-3′ human-MMP-10-R/119: 5′-TCATGAGCAGCAACGAGG-AA-3′ human-MMP-2-F/222: 5′-CCGCCTTTAACTGGAGCAAA-3′ human-MMP-2-R/222: 5′-TTTGGTTCTCCAGCTTCAGG-3′ human-MMP-10 promoter-F/149: 5′-ACCAAGCTTGTCA-GCTCTCTTT-3′ human-MMP-10 promoter-R/149: 5′-CAGCCTACATC-AGTATTTTCCTTCA-3′
Kras Mutation Analyses
Kras and Nras mutations (codon: 12, 13, 59, 61, 117, 146) were analyzed by the PCR-reverse sequence specific oligonucleotide (PCR-rSSO) method as described. 24 Briefly, genomic DNA was obtained from xenograft tumor tissue samples. Tissue samples were fixed in 10% phosphate-buffered formalin overnight and embedded in paraffin. Ten-micron sections were prepared using formalin-fixed, paraffin-embedded tissues, placed on coated glass slides, and dried at room temperature overnight. The samples were sent to the research institution (SRL, Tokyo, Japan). Genomic DNA was isolated from the samples and 50 ng of template DNA was amplified by PCR using a biotin-labeled primer. The PCR products and fluorescent beads (oligonucleotide probes complementary to wild and mutant genes were bound to the beads) were hybridized and labeled with streptavidin-phycoerythrin. The products were subjected to PCR-rSSO assays and collected data were analyzed using UniMAG software (MBL, Nagoya, Japan).
Immunoblotting KMC07 cells, co-cultured with PA6 cells in a 6-well Costar cell culture plate (Thermo Fisher Scientific Inc), were treated with 0.125 μM gemcitabine for 48 hours. Cells were washed twice with 3 mL of ice-cold PBS and resuspended with 200 μL of Laemmli sample loading buffer (2% SDS, 20 mM dithiothreitol, 10% glycerol, 62.5 mM Tris-HCl [pH 6.8], and 0.002% bromophenol blue). The samples were sonicated for 10 seconds and boiled for 5 minutes. The samples were subjected to SDS-PAGE, along with molecular weight markers, Precision Pus Protein Standards Unstained Protein Standards (catalog number 161-0363, BioRad, Hercules, Calif) and Precision Plus Protein Kaleidoscope Standards (catalog number 161-0375, Bio-Rad), using e-PAGEL 5%-20% gel (catalog number E-T520L; ATTO, Tokyo, Japan). Proteins were transferred from the gel to a nitrocellulose membrane (iBlot gel Transfer Stacks Nitrocellulose, Mini, Thermo Fisher Scientific Inc) for 7 minutes using the iBlot Gel Transfer System (catalog number IB1001; Invitrogen) according to manufacturers' protocols. The blotted membrane was rinsed with PBS for 5 minutes, and blocked with 5% skim milk in TBST at room temperature for 1 hour. The membrane was washed 3 times with 25 mL of TBST for 5 minutes and incubated with a primary antibody (a rabbit antihuman MMP-10 polyclonal antibody diluted 1:100 in 5% bovine serum albumin [BSA] in TBST) at 4°C overnight. The membrane was rinsed 3 times with TBST for 5 minutes, and incubated with a secondary antibody (an horseradish peroxidase [HRP]-conjugated goat antirabbit IgG [H + L] (catalog number G-21234; Thermo Fisher Scientific Inc) diluted 1:20,000 in TBST with 5% BSA) and StrepTactin-HRP conjugate (catalog number 161-0382; Bio-Rad) diluted 1:20,000 in TBST with 5% BSA at room temperature for 1 hour. The membrane was rinsed 5 times with TBST for 5 minutes, and incubated with the SuperSignal West Dura Extended Duration Substrate (catalog number 34075; Thermo Fisher Scientific Inc.) according to a manufacturer's protocol. The chemiluminescent signals were captured using a CCD camera-based imager (Optima Shot CL-420α; Wako Pure Chemical Industries, Osaka, Japan) and analyzed using software (Basic Quantifier v.3.3.5; Bio Image Systems Inc, Tokyo, Japan). To detect human CoxIV (3E11) protein as an endogenous control, the blotted membrane was incubated with an HRP-conjugated rabbit antihuman CoxIV monoclonal antibody (catalog number 5247; Cell Signaling Technology, Danvers, Mass) diluted 1:1000 in TBST with 5% BSA in at room temperature for 1 hour.
ChIP Analyses
The ChIP assays were performed using the Acetyl-Histone H3 Immunoprecipitation (ChIP) Assay Kit (catalog number 17-245; Millipore Corp, Billerica, Mass) according to the manufacturer's protocol. Briefly, KMC07 cells were cocultured with PA6 cells with 4 mL of Stem medium in a 10-cm Corning culture dish and treated with 0.125 μM gemcitabine or PBS for 48 hours. One milliliter of 10% formalin solution (catalog number 060-03845; Wako Pure Chemical Industries) was added to each dish and cells were incubated at 37°C for 10 minutes. Cells were washed twice with 5 mL of ice-cold PBS with a protease inhibitor cocktail (cOmplete, catalog number 11697498001; Roche Diagnostics, Basel, Switzerland) on ice, harvested using a cell scraper (catalog number 9000-220; AGC Techno Glass Co, Ltd, Shizuoka, Japan) into a 1.5-mL conical tube, and pelleted by a centrifugation at 2000g at 4°C for 4 minutes. Cells (approximately 1 Â 10 6 cells) were re-suspended in 200 μL of SDS Lysis Buffer (catalog number 20-163; Millipore) with a protease inhibitor cocktail and incubated for 10 minutes on ice. The lysate was sonicated 6 times using an Ultrasonic Disrupter (Handy Sonic UR-20P; TOMY, Tokyo, Japan) at 20 Watts for 30 seconds on ice (at 5-minute intervals). The samples were centrifuged at 21,500g at 4°C for 10 minutes, and the supernatants were transferred into a 2-mL conical tube and diluted with 1800 μL of ChIP Dilution Buffer (catalog number 20-153; Millipore). A 200-μL aliquot of the diluted sample was transferred to another tube as an "in-put sample." The remaining samples were incubated with 75-μL Salmon Sperm DNA/Protein A Agarose-50% Slurry (catalog number 16-157; Millipore) at 4°C for 30 minutes with rotation and centrifuged at 1000g at 4°C for 1 minute. The supernatant was transferred to a conical tube and incubated with 4 μL of a rabbit anti-acetyl-Histone H3 polyclonal antibody (catalog number 06-599; Millipore) at 4°C overnight with constant rotation. Sixty microliters of Salmon Sperm DNA/Protein A Agarose-50% Slurry was added to the conical tube and incubated at 4°C for 1 hour with constant rotation. After centrifugation at 1000g at 4°C for 1 minute, the supernatant was removed and the Protein ; Millipore) at 4°C. The Protein A agarose was incubated with 250 μL of elution buffer (1% SDS and 0.1 M NaHCO 3 ) for 15 minutes and centrifuged at 1000g for 1 minute at room temperature. The supernatant was transferred to another tube, and this elution procedure was repeated. The combined supernatant (total 500 μL), "elution sample", and "in-put sample" (total, 200 μL) were mixed with 5 M NaCl (final concentration, 0.2 M) and incubated at 65°C for 4 hours. After incubation, the samples were mixed with reaction buffer (final concentration: 36 mM Tris-HCl (pH 6.5), 18 mM ethylenediaminetetraacetic acid, 0.18 M NaCl, and 0.36 g/L Proteinase K (catalog number MC5005; Promega, Madison, Wis), and incubated further at 45°C for 1 hour. The samples were treated with an equal volume of phenol/chloroform/ isoamyl alcohol mixed, pH 7.9 (catalog number 25970-14; Nacarai Tesque, Kyoto, Japan) and precipitated with ethanol and linear polyacrylamide prepared as described. 25 The precipitates were washed with 70% ethanol and dissolved in 20 μL of DNase-free water, followed by qRT-PCR using human MMP-10 promoter primers.
Statistical Analyses
Results for continuous variables were expressed as the mean ± SE. Statistically significant differences were determined by the Student's t-test. Significance was defined as P less than 0.05.
This study was performed according to Institutional Review Board-approved guidelines in Kobe Medical Center and Kobe University School of Health Sciences and approved by the Ethics Committees of Kobe Medical Center and Kobe University School of Health Sciences (permission no. 152).
RESULTS
MMP-10 mRNA Expression Was Upregulated by Gemcitabine in KMC07 Cells
We previously isolated and characterized seven pancreatic tumor-initiating cell lines from 7 independent PDAC patients who were resistant to gemcitabine treatment. 19 The KMC07 patient was treated with gemcitabine for 3 years. His liver metastases disappeared and his pancreatic tumor became smaller (partial response) for the first two years of treatment. After the partial response, the liver metastases slowly recurred, accompanied by peritoneal dissemination for the last year of treatment (Fig. 1A) . The KMC07 cell line was derived from the KMC07 patient, suggesting that KMC07 cells might have acquired, or congenitally possess, gemcitabine resistance. Engraftment of KMC07 cells into the pancreatic tail or subcutaneous fat of nude mice resulted in the formation of tumors, accompanied by liver and lung metastases (Fig. 1B) . To identify genes in KMC07 cells that are upregulated in response to gemcitabine, KMC07 cells were treated with or without gemcitabine, then subjected to microarray analyses. We found that MMP-10 was the most highly induced gene on the array, followed by synaptotagmin XVI and transmembrane protein 40 (Fig. 1C) .
In this study, we characterized the interaction between MMP-10 mRNA upregulation and gemcitabine resistance. We examined MMP-10 mRNA expression levels in KMC07 cells and the cultured pancreatic cancer cell lines: BXPC-3, MIA PaCa-2, PANC-1, and AsPC-1 cells. KMC07 cells, but 
none of the other cultured cell lines, expressed MMP-10 mRNA, which was upregulated upon gemcitabine treatment. KMC07 cells did not express MMP-2 mRNA; a gene expressed by PANC-1 cells (Fig. 2A) . 26 Gemcitabine upregulated MMP-10 mRNA expression in KMC07 cells in a dose-dependent manner (Fig. 2B) . We also confirmed that gemcitabine upregulated MMP-10 protein expression in KMC07 cells (Fig. 2C) .
Upregulation of Kras-MEK-Induced MMP-10 mRNA Expression by Gemcitabine
We confirmed that KMC07 cells expressed the Kras CA mutant, Kras
G12V
, by the PCR-rSSO method (Fig. 3A) . We asked if the Kras G12V signaling pathway regulates gemcitabine-enhanced MMP-10 expression. A MEK inhibitor, U0126, reduced the basal level of MMP-10 mRNA expression in KMC07 cells, in the absence of gemcitabine (Fig. 3B) . Moreover, U0126 suppressed gemcitabine-enhanced expression of MMP-10 Requirement of Histone Acetylation for Gemcitabine-Dependent MMP-10 mRNA Expression
We examined whether histone acetylation was involved with gemcitabine-enhanced MMP-10 expression in KMC07 cells. Gemcitabine-enhanced MMP-10 mRNA expression was reduced by C646, a histone acetyltransferase inhibitor (Fig. 4A) . Trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, enhanced MMP-10 mRNA expression, while C646 reduced TSA-enhanced MMP-10 mRNA expression (Fig. 4B) . TSA-enhanced MMP-10 mRNA expression was reduced by U0126 (Fig. 4B) . Gemcitabine exhibited enhanced histone H3 acetylation level at an MMP-10 promoter in ChIP assays (Fig. 4C ). These results demonstrate that histone acetylation is required for gemcitabine-induced upregulation of MMP-10 mRNA expression.
Induction of MMP-10 Protein Expression in KMC07-Derived Tumor by Gemcitabine In Vivo
Gemcitabine reduced the growth rate of KMC07-derived subcutaneous tumors in nude mice (Fig. 5A ). To test whether gemcitabine upregulated MMP-10 expression in KMC07-derived tumors, KMC07 cells were injected into a region of the pancreas tail of nude mice and gemcitabine subsequently administered intraperitoneally. The growth rate of KMC07-derived orthotopic pancreatic tumor was also reduced in the presence of gemcitabine (Fig. 5B) . Histologically, gemcitabine enhanced the invasion of KMC07-derived tumor cells into normal pancreas tissues, and partially upregulated MMP-10 expression, whereas in the absence of gemcitabine, KMC07-derived tumor cells grew expansively within the fibrous capsule (Fig. 5B) . These results suggest that gemcitabine upregulates MMP-10 protein expression in KMC07-derived orthotopic pancreatic tumors.
DISCUSSION
This is the first demonstration that the gemcitabine-enhanced Kras G12V -MEK-MMP-10 signaling pathway was activated in gemcitabine-resistant PDAC in vivo and in vitro. This suggests that acquiring gemcitabine resistance may unlock the Kras G12V signaling pathway that is inactivated in naive PDAC.
The KMC07 cell line characterized in this study is one of 7 KMC cell lines that we have previously reported. 19 The 6 other KMC cell lines also expressed MMP-10 mRNA at levels similar to that of the KMC07 cell line in the absence of gemcitabine (data not shown). The MMP-10 was required for invasion and metastasis of pancreatic cancer. 16 The MMP-10 cleaved collagen type 1 in co-operation with MMP-1, resulting in re-organization of the extracellular matrix. 27 The MMP-1 was also required for Kras CA mutant-regulated invasion of human pancreatic cancer cells via ERK2. 28 Taken together, these results suggest that KMC07 cells re-organize extracellular matrix through Kras G12V -induced activation of MMP-10, followed by invasion and metastasis. MIA PaCa-2, PANC-1, and AsPC-1 cells, but not BxPC-3 cells express the Kras CA mutant. 29 However, MIA PaCa-2, PANC-1, and AsPC-1 cells, did not express MMP-10 mRNA. If presence of the Kras CA mutation was sufficient to induce MMP-10 mRNA expression, these cultured cell lines would express MMP-10 mRNA. Therefore, our results indicate that a Kras CA mutation is necessary, but not sufficient for MMP-10 induction, and that other unknown factors might be required for Kras CA mutant-MEK-dependent induction of MMP-10.
A low level of histone acetylation in pancreatic cancer is a predictor of poor survival 30 and HDAC inhibitors are currently being evaluated in trials. 31, 32 In contrast, we showed that gemcitabine enhanced histone H3 acetylation levels at an MMP-10 promoter, and that this was reduced by a histone acetyltransferase inhibitor. Moreover, TSA enhanced the MMP-10 mRNA expression level in KMC07 cells, consistent with a previous report that HDAC-7 repressed MMP-10 gene transcription by associating with myocyte enhancer factor-2. 18 Another group recently showed that gemcitabine treatment increased histone acetylation levels at a prooncogenic molecule miR-21 promoter in cultured pancreatic cancer cell lines. 33, 34 Taken together, these results suggest that the effects of histone acetylation on PDAC may be context-dependent. It remains unknown how gemcitabine increases histone H3 acetylation levels at the MMP-10 promoter, however, it is possible that gemcitabine blocks DNA replication and leads to a DNA damage response that includes acetylation of histones in a context-dependent manner. 35, 36 We showed that gemcitabine-enhanced MMP-10 expression was completely inhibited by a MEK inhibitor, U0126. 37 A Notch inhibitor, N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-(S)-phenylglycine t-butyl ester, 38 and a TGF-β receptor antagonist, SB431542, 39 partially reduced gemcitabine-enhanced MMP-10 mRNA expression (data not shown). Therefore, the Kras
G12V
-MEK signaling pathway is necessary for MMP-10 expression, and Notch and TGF-β signals might function as enhancers for MMP-10 expression.
To improve the anticancer effects of gemcitabine on PDAC, molecular mechanisms of gemcitabine resistance are under intense investigation. 3 Our results demonstrate a unique gemcitabine-resistance mechanism using novel pancreatic tumor-initiating cells, and suggest that not only MMP-10, but also other cancer-related genes downstream of Kras G12V signaling pathways, may be activated when PDAC becomes resistant to gemcitabine. It is possible that a combination of gemcitabine and MEK inhibitors, as well as MMP-10 inhibitors, might synergistically improve the overall survival of gemcitabine-resistant PDAC patients.
